Diastolic blood pressure (setting unspecified)

Method

Brachial diastolic blood pressure by cuff sphygmomanometry or a validated automated device, pooled across trials whose acquisition protocol the source report does not record. The defining property of this node is that the acquisition conditions are unrecoverable from the published pooled estimate.

The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.

Notes

Systolic blood pressure comes from the same cuff inflation and is printed in the same sentence, yet the two dissociate systematically in this batch — PMID 41000008 finds magnesium moving both while PMID 40045266 finds only the diastolic component, a disagreement that is only visible if they are separate nodes. Also distinct from diastolic blood pressure (office/clinic), where the seated clinic visit is documented and the value can be assumed free of ambulatory averaging; pooling the two asserts an acquisition protocol the source declined to state. Direction of benefit is a property of the endpoint, not of the observed result: PMID 18054420 reported a RISE with maca as a safety signal, and that is a harmful finding on this node, not a reason to re-sign it.

Findings

8 findings from 5 compounds, strongest first.

• resveratrol — decreases

  BLikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding

  “The results illustrated a significant reduction in the DBP by resveratrol after removing these studies (WMD: −3.55 mmHg, 95% CI: −5.18, −1.93; P < 0.0001;.”

  Study

  meta-analysis

  Dose

  8.1-3000 mg/day resveratrol across the pooled trials

  Population

  Adults with type 2 diabetes; secondary endpoint, pooled after excluding two high-heterogeneity trials, resveratrol vs placebo

  Effect -3.55 mean difference, 95% CI -5.18 to -1.93

  Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602

• nitrate — no detected effect on

  BLikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result

  “No significant effects of nitrate supplementation were observed on body weight, BMI, or diastolic blood pressure (DBP).”

  Study

  meta-analysis

  Population

  adults with obesity

  The effect of dietary nitrate on weight management: a systematic review and meta-analysis.2026PMID:42130877

• magnesium(2+) — decreases

  BLikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding

  “Magnesium intake resulted in a reduction in systolic BP of -2.81 mm Hg (95% CI, -4.32 to -1.29) and diastolic BP by -2.05 mm Hg (95% CI, -3.23 to -0.88) compared with placebo.”

  Study

  meta-analysis

  Dose

  median 365 mg/d elemental magnesium (range 82.3-637 mg), median intervention period 12 weeks

  Population

  hypertensive and normotensive adults in randomized controlled trials of at least 4 weeks

  Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:41000008

• curcumin — no detected effect on

  BLikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×1

  “Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”

  Study

  meta-analysis

  Dose

  80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)

  Population

  Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate

  Effect -0.02 mean difference, 95% CI -0.55 to 0.52

  An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891

• curcumin — no detected effect on

  BLikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull resultreplicated ×1

  “Meta‐analysis of 16 effect sizes demonstrated no significant alteration in DBP following supplementation of curcumin/turmeric compared to control groups (WMD: −1.20 mmHg; 95% CI: −2.84 to 0.44; p = 0.15) (Figure.”

  Study

  meta-analysis

  Population

  adults with prediabetes or type 2 diabetes; primary endpoint

  Effect -1.2 mean difference, 95% CI -2.84 to 0.44

  Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.2026PMID:41388744

• melatonin — no detected effect on

  CSuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1

  “Mean Daytime Diastolic Blood Pressure (DBP) (SECONDARY, mmHg) -- NCT01114360: Melatonin 85.7 +/-1.6 (n=36) vs Placebo 86.2 +/-1.7 (n=36); difference -0.5; p=0.89, no significant difference”

  Study

  crossover

  Participants

  72

  Population

  Hypertension; 18 Years+

  Effect -0.5 mean difference

  Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360

• melatonin — no detected effect on

  CSuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1

  “Mean Nighttime Diastolic Blood Pressure (DBP) (PRIMARY, mmHg) -- NCT01114360: Melatonin 76 +/-1.7 (n=36) vs Placebo 76.2 +/-1.8 (n=36); difference -0.2; p=0.75, no significant difference”

  Study

  crossover

  Participants

  72

  Population

  Hypertension; 18 Years+

  Effect -0.2 mean difference

  Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360

• melatonin — no detected effect on

  CSuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1

  “Mean Daytime Diastolic Blood Pressure (DBP) (SECONDARY, mmHg) -- NCT01114373: Melatonin 85.3 +/-1.8 (n=36) vs Placebo 86.6 +/-1.8 (n=36); difference -1.3; p=0.12, no significant difference”

  Study

  crossover

  Participants

  72

  Population

  Hypertension; 18 Years+

  Effect -1.3 mean difference

  Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study2015NCT01114373